Sermorelin, a nightly injection, prompts the pituitary to release the body's own growth hormone in natural bursts. It most solidly restores growth hormone toward youthful levels and modestly reduces deep abdominal fat. Benefits for muscle, sleep, skin, and recovery rest mainly on reasoning and user reports. Short-term use is well tolerated; long-term safety and true longevity payoff remain unresolved. (Full Review)
| Marker | Target | Why |
|---|---|---|
| IGF-1 | Upper-middle of age-adjusted range, not above | Primary marker of GH-axis response and main dosing target |
| Fasting glucose | 70–90 mg/dL | Detects GH-related reduction in insulin sensitivity |
| HbA1c | < 5.4% | Detects sustained glucose dysregulation over time |
| Fasting insulin | 2–5 µIU/mL | Early marker of insulin resistance before glucose rises |
| TSH | 0.5–2.5 mIU/L | Untreated hypothyroidism blunts the GH response |
| Fasting lipid panel | Standard functional targets | GH axis and body-composition changes can shift lipids |
Cadence: Baseline, at 4–8 weeks after starting or changing dose, then every 3–6 months (more frequent glucose checks with metabolic risk)